Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Equity Average (2019 - 2025)

Historic Equity Average for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $23.5 million.

  • Eton Pharmaceuticals' Equity Average rose 5992.6% to $23.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.5 million, marking a year-over-year increase of 5992.6%. This contributed to the annual value of $20.0 million for FY2024, which is 3974.79% up from last year.
  • Eton Pharmaceuticals' Equity Average amounted to $23.5 million in Q3 2025, which was up 5992.6% from $24.2 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Equity Average peaked at $24.4 million during Q1 2025, and registered a low of $12.1 million during Q4 2022.
  • For the 5-year period, Eton Pharmaceuticals' Equity Average averaged around $17.1 million, with its median value being $16.2 million (2023).
  • Its Equity Average has fluctuated over the past 5 years, first soared by 33230.79% in 2021, then plummeted by 3704.33% in 2022.
  • Over the past 5 years, Eton Pharmaceuticals' Equity Average (Quarter) stood at $16.6 million in 2021, then decreased by 27.13% to $12.1 million in 2022, then soared by 33.43% to $16.2 million in 2023, then rose by 24.84% to $20.2 million in 2024, then rose by 16.53% to $23.5 million in 2025.
  • Its last three reported values are $23.5 million in Q3 2025, $24.2 million for Q2 2025, and $24.4 million during Q1 2025.